Biologic targets identified from dynamic ¹⁸FDG-PET and implications for image-guided therapy

References

• Hoshikawa H, Kishino T, Nishiyama Y, Yamamoto Y, Yonezaki M, Mori N. Early prediction of local control in head and neck cancer after chemoradiotherapy by FDG-PET. Nucl Med Commun 2011;32:684–9.
   PubMed Web of Science ®Google Scholar
• Machtay M, Natwa M, Andrel J, Hyslop T, Anne PR, Lavarino J, et al. Pretreatment FDG-PET standardized uptake value as a prognostic factor for outcome in head and neck cancer. Head Neck 2009;31:195–201.
   PubMed Web of Science ®Google Scholar
• Bertagna F, Giubbini R. F18-FDG-PET/CT standardised uptake value threshold in discriminating benign vs. malignant lesions. Doubts and certainties in the era of evidence-based medicine. Acta Oncol 2012;51:122–44.
   PubMed Web of Science ®Google Scholar
• van Elmpt W, De Ruysscher D, van der Salm A, Lakeman A, van der Stoep J, Emans D, et al. The PET-boost randomised phase II dose-escalation trial in non-small cell lung cancer. Radiother Oncol 2012;104:67–71.
   PubMed Web of Science ®Google Scholar
• van Loon J, van Baardwijk A, Boersma L, Ollers M, Lambin P, De Ruysscher D. Therapeutic implications of molecular imaging with PET in the combined modality treatment of lung cancer. Cancer Treat Rev 2011;37:331–43.
   PubMed Web of Science ®Google Scholar
• Ashamalla H, Guirgius A, Bieniek E, Rafla S, Evola A, Goswami G, et al. The impact of positron emission tomography/computed tomography in edge delineation of gross tumor volume for head and neck cancers. Int J Radiat Oncol Biol Phys 2007;68:388–95.
   PubMed Web of Science ®Google Scholar
• Duprez F, Bonte K, De Neve W, Boterberg T, De Gersem W, Madani I. Regional relapse after intensity-modulated radiotherapy for head-and-neck cancer. Int J Radiat Oncol Biol Phys 2011;79:450–8.
   PubMed Web of Science ®Google Scholar
• Dirix P, Vandecaveye V, De Keyzer F, Stroobants S, Hermans R, Nuyts S. Dose painting in radiotherapy for head and neck squamous cell carcinoma: Value of repeated functional imaging with (18)F-FDG PET, (18)F-fluoromisonidazole PET, diffusion-weighted MRI, and dynamic contrast-enhanced MRI. J Nucl Med 2009;50:1020–7.
   PubMed Web of Science ®Google Scholar
• Ashton E, Riek J. Advanced MR techniques in multicenter clinical trials. J Magn Reson Imaging 2013;37:761–9.
   PubMed Web of Science ®Google Scholar
• Zahra MA, Hollingsworth KG, Sala E, Lomas DJ, Tan LT. Dynamic contrast-enhanced MRI as a predictor of tumour response to radiotherapy. Lancet Oncol 2007;8:63–74.
   PubMed Web of Science ®Google Scholar
• Dimitrakopoulou-Strauss A, Strauss LG, Egerer G, Vasamiliette J, Schmitt T, Haberkorn U, et al. Prediction of chemotherapy outcome in patients with metastatic soft tissue sarcomas based on dynamic FDG PET (dPET) and a multiparameter analysis. Eur J Nucl Med Mol Imaging 2010;37:1481–9.
   PubMed Web of Science ®Google Scholar
• Revheim ME, Kristian A, Malinen E, Bruland OS, Berner JM, Holm R, et al. Intermittent and continuous imatinib in a human GIST xenograft model carrying KIT exon 17 resistance mutation D816H. Acta Oncol 2013;52:776–82.
   PubMed Web of Science ®Google Scholar
• Bussink J, Kaanders JH, van der Graaf WT, Oyen WJ. PET-CT for radiotherapy treatment planning and response monitoring in solid tumors. Nat Rev Clin Oncol 2011;8: 233–42.
   PubMed Web of Science ®Google Scholar
• Histed SN, Lindenberg ML, Mena E, Turkbey B, Choyke PL, Kurdziel KA. Review of functional/anatomical imaging in oncology. Nucl Med Commun 2012;33:349–61.
   PubMed Web of Science ®Google Scholar
• Lips IM, van der Heide UA, Haustermans K, van Lin EN, Pos F, Franken SP, et al. Single blind randomized phase III trial to investigate the benefit of a focal lesion ablative microboost in prostate cancer (FLAME-trial): Study protocol for a randomized controlled trial. Trials 2011;12:255.
   PubMed Web of Science ®Google Scholar
• Rusten E, Rodal J, Revheim ME, Skretting A, Bruland OS, Malinen E. Quantitative dynamic (18)FDG-PET and tracer kinetic analysis of soft tissue sarcomas. Acta Oncol Epub 2012 Dec 3.
   PubMed Web of Science ®Google Scholar
• Cochet A, Pigeonnat S, Khoury B, Vrigneaud JM, Touzery C, Berriolo-Riedinger A, et al. Evaluation of breast tumor blood flow with dynamic first-pass 18F-FDG PET/CT: Comparison with angiogenesis markers and prognostic factors. J Nucl Med 2012;53:512–20.
   PubMed Web of Science ®Google Scholar
• Malinen E, Rodal J, Knudtsen IS, Sovik A, Skogmo HK. Spatiotemporal analysis of tumor uptake patterns in dynamic (18)FDG-PET and dynamic contrast enhanced CT. Acta Oncol 2011;50:873–82.
   PubMed Web of Science ®Google Scholar
• Mullani NA, Herbst RS, O’Neil RG, Gould KL, Barron BJ, Abbruzzese JL. Tumor blood flow measured by PET dynamic imaging of first-pass 18F-FDG uptake: A comparison with 15O-labeled water-measured blood flow. J Nucl Med 2008;49:517–23.
   PubMed Web of Science ®Google Scholar
• Roe K, Aleksandersen TB, Kristian A, Nilsen LB, Seierstad T, Qu H, et al. Preclinical dynamic 18F-FDG PET – tumor characterization and radiotherapy response assessment by kinetic compartment analysis. Acta Oncol 2010;49:914–21.
   PubMed Web of Science ®Google Scholar
• Chung JK, Lee YJ, Kim SK, Jeong JM, Lee DS, Lee MC. Comparison of [18F]fluorodeoxyglucose uptake with glucose transporter-1 expression and proliferation rate in human glioma and non-small-cell lung cancer. Nucl Med Commun 2004;25:11–7.
   PubMed Web of Science ®Google Scholar
• Park SG, Lee JH, Lee WA, Han KM. Biologic correlation between glucose transporters, hexokinase-II, Ki-67 and FDG uptake in malignant melanoma. Nucl Med Biol 2012;39:1167–72.
   PubMed Web of Science ®Google Scholar
• Tohma T, Okazumi S, Makino H, Cho A, Mochiduki R, Shuto K, et al. Relationship between glucose transporter, hexokinase and FDG-PET in esophageal cancer. Hepatogastroenterology 2005;52:486–90.
   PubMed Web of Science ®Google Scholar
• Marusyk A, Almendro V, Polyak K. Intra-tumour heterogeneity: A looking glass for cancer?. Nat Rev Cancer 2012;12: 323–34.
   PubMed Web of Science ®Google Scholar
• Jansen JF, Schoder H, Lee NY, Stambuk HE, Wang Y, Fury MG, et al. Tumor metabolism and perfusion in head and neck squamous cell carcinoma: Pretreatment multimodality imaging with 1H magnetic resonance spectroscopy, dynamic contrast-enhanced MRI, and [18F]FDG-PET. Int J Radiat Oncol Biol Phys 2012;82:299–307.
   PubMed Web of Science ®Google Scholar
• Chiche J, Brahimi-Horn MC, Pouyssegur J. Tumour hypoxia induces a metabolic shift causing acidosis: A common feature in cancer. J Cell Mol Med 2010;14:771–94.
   PubMed Web of Science ®Google Scholar
• Gatenby RA, Gillies RJ. Glycolysis in cancer: A potential target for therapy. Int J Biochem Cell Biol 2007;39:1358–66.
   PubMed Web of Science ®Google Scholar
• Gillies RJ, Verduzco D, Gatenby RA. Evolutionary dynamics of carcinogenesis and why targeted therapy does not work. Nat Rev Cancer 2012;12:487–93.
   PubMed Web of Science ®Google Scholar
• Groenendaal G, van den Berg CA, Korporaal JG, Philippens ME, Luijten PR, van Vulpen M, et al. Simultaneous MRI diffusion and perfusion imaging for tumor delineation in prostate cancer patients. Radiother Oncol 2010; 95:185–90.
   PubMed Web of Science ®Google Scholar
• Nyflot MJ, Harari PM, Yip S, Perlman SB, Jeraj R. Correlation of PET images of metabolism, proliferation and hypoxia to characterize tumor phenotype in patients with cancer of the oropharynx. Radiother Oncol 2012;105:36–40.
   PubMed Web of Science ®Google Scholar
• Flynn RT, Barbee DL, Mackie TR, Jeraj R. Comparison of intensity modulated x-ray therapy and intensity modulated proton therapy for selective subvolume boosting: A phantom study. Phys Med Biol 2007;52:6073–91.
   PubMed Web of Science ®Google Scholar